Rigel Pharmaceuticals, Inc. Quarterly report [Sections 13 or 15(d)]

CASH, CASH EQUIVALENTS, RESTRICTED CASH, AND SHORT-TERM INVESTMENTS (Tables)

3 Months Ended

Mar. 31, 2025

Cash, cash equivalents, restricted cash, and short-term investments for the periods presented consist of the following (in thousands):


	As of
	March 31, 2025		December 31, 2024
Cash	$	19,591	$	20,135
Restricted cash		57		—
Money market funds		11,186		16,386
US treasury bills		8,915		7,263
Government-sponsored enterprise securities		15,874		23,177
Corporate bonds and commercial paper		21,533		10,360
	$	77,156	$	77,321
Reported as:
Cash and cash equivalents	$	45,728	$	56,746
Short-term investments		31,371		20,575
Restricted cash reported within other assets		57		—
	$	77,156	$	77,321

Cash equivalents and short-term investments include the following securities with gross unrealized gains and losses (in thousands):


			Gross		Gross
	Amortized		Unrealized		Unrealized
As of March 31, 2025	Cost		Gains		Losses		Fair Value
US treasury bills	$	8,913	$	2	$	—	$	8,915
Government-sponsored enterprise securities		15,875		1		(2)		15,874
Corporate bonds and commercial paper		21,536		2		(5)		21,533
Total	$	46,324	$	5	$	(7)	$	46,322


			Gross		Gross
	Amortized		Unrealized		Unrealized
As of December 31, 2024	Cost		Gains		Losses		Fair Value
US treasury bills	$	7,260	$	3	$	—	$	7,263
Government-sponsored enterprise securities		23,174		3		—		23,177
Corporate bonds and commercial paper		10,356		4		—		10,360
Total	$	40,790	$	10	$	—	$	40,800


As of March 31, 2025	Fair Value		Gross Unrealized Losses
Government-sponsored enterprise securities	$	5,696	$	(2)
Corporate bonds and commercial paper		14,575		(5)
Total	$	20,271	$	(7)